MedPath

A randomized, triple-arm study to compare the viral and immunological outcome of HAART during 6 versus 15 months versus no treatment in patients with primary HIV 1 infection.

Completed
Registration Number
NL-OMON20081
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
173
Inclusion Criteria

Diagnosis of acute/ recent HIV-1 infection: plasma HIV-1 RNA load detectable and/or detectable serum p24 antigen and one of the following:

1. ELISA: HIV-1 specific antibodies negative;

Exclusion Criteria

1. Previous test result with HIV-1 RNA detectable or P24 antigen positive > 180 days before presentation;

2. For female subjects: pregnancy (positive urine pregnancy test) or breast feeding.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath